| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | DASS-397D15.1 ELISA Kit; DR alpha chain ELISA Kit; DR alpha chain precursor ELISA Kit; DRA_HUMAN ELISA Kit; DRB1 ELISA Kit; DRB4 ELISA Kit; FLJ51114 ELISA Kit; Histocompatibility antigen HLA DR alpha ELISA Kit; Histocompatibility antigen HLA-DR alpha ELISA Kit; HLA class II histocompatibility antigen ELISA Kit; HLA class II histocompatibility antigen DR alpha chain ELISA Kit; HLA DR1B ELISA Kit; HLA DR3B ELISA Kit; HLA DRA ELISA Kit; HLA DRA1 ELISA Kit; HLA DRB1 ELISA Kit; HLA DRB3 ELISA Kit; HLA DRB4 ELISA Kit; HLA DRB5 ELISA Kit; HLA-DR histocompatibility type ELISA Kit; HLA-DRA ELISA Kit; HLADR4B ELISA Kit; HLADRA1 ELISA Kit; HLADRB ELISA Kit; Major histocompatibility complex class II DR alpha ELISA Kit; Major histocompatibility complex class II DR beta 1 ELISA Kit; Major histocompatibility complex class II DR beta 3 ELISA Kit; Major histocompatibility complex class II DR beta 4 ELISA Kit; Major histocompatibility complex class II DR beta 5 ELISA Kit; MGC117330 ELISA Kit; MHC cell surface glycoprotein ELISA Kit; MHC class II antigen DRA ELISA Kit; MHC II ELISA Kit; MLRW ELISA Kit; OTTHUMP00000029406 ELISA Kit; OTTHUMP00000029407 ELISA Kit |
| Assay Time | |
| Assay Type | |
| Detection Range | |
| Detection Wavelength | |
| Product Type | |
| Reactivity | |
| Sample Type(s) | serum, plasma, tissue homogenates |
| Sensitivity | |
| Species | |
| Target | |
| UniProt # |
Background
HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) is a biological molecule commonly studied in immunology research. It is commonly used as a molecular readout in mechanistic and biomarker-focused studies.
UniProt: P01903
Biological context
Researchers often monitor HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) in serum, plasma, and tissue homogenates to better understand themes such as innate and adaptive immune responses, cytokine signaling networks, and host–pathogen interactions. In many model systems, measured levels can shift with physiology, experimental perturbation, or disease-associated changes, making careful biological interpretation important.
Interpreting changes in measured levels
Depending on sample matrix and study design, increases or decreases in HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) may reflect differences in expression, secretion, turnover, or compartmentalization rather than a single mechanism. Interpretation is typically strengthened by evaluating related molecules (for example, cytokines, chemokines, acute-phase proteins, and immune-cell activation markers) and by keeping pre-analytical variables consistent across groups.
Nomenclature
In publications and databases, HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) may also appear under names such as DASS-397D15.1 and DR alpha chain. When comparing studies, confirm that the reported analyte refers to the same molecule and species context.
Why ELISA data are widely used
ELISA is a common approach for quantitative measurement of proteins and biomarkers in complex samples, enabling comparisons across experimental groups and time points. When integrating results with other readouts, consider species biology, sample type, and the broader pathway context that HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) participates in.
Can’t Find What You’re Looking For? We can help you source the best match or customize an ELISA solution for your study. Options may include alternative target synonyms, different species reactivity, sample type/matrix compatibility (serum/plasma/lysate/supernatant), assay format (sandwich/competitive), sensitivity/range, detection chemistry (colorimetric/fluorescent/chemiluminescent), plate format (pre-coated/uncoated, strips vs full plate), and bulk or custom packaging. Click Talk to a Scientist to submit a request form, email us at support@biohippo.com, or explore our Research Services for additional support. Our team will be in contact with you shortly.
Therapeutic effects of simvastatin combined with kallistatin treatment for pediatric burn patients with sepsis
Dai Y,Experimental and therapeutic medicine,2023